Cancer research firm CG Oncology Inc., which has a novel treatment that’s been called a “game changer” for bladder cancer, is aiming for a $1 billion valuation when it goes public in the coming days.

Five months after reeling in $105 million from a pre-IPO crossover round, CG Oncology is now ready to take the plunge and go public. The company has yet to reveal an estimate for how much the shares ...

CG Oncology’s late-stage bladder cancer treatment notched a complete response in roughly three-quarters of treated patients, fueling optimism that the company’s Wall Street success story is no fluke.